[Clinical studies of ifosfamide for gynecological malignancies]. 1983

I Kohno, and M Kazuta, and J Miyao, and N Kunimi, and M Kawamoto, and T Tanimura, and K Fujiwara, and K Sekiba

This study was performed to evaluate the clinical effect and the side effect of ifosfamide in the treatment of gynecological malignancies. A total of 18 cases were treated with ifosfamide: 11 of them were treated as a single agent and the remaining 7 cases were treated as a combination chemotherapy. A daily dose of 1.5-2.0 grams were given for 5 consecutive days. The number of course varied from one to five. Six (35.3%) out of 17 evaluable cases showed partial response. Three were treated with ifosfamide alone and the another three were with a combination chemotherapy. The side effect such as leukopenia, gastrointestinal disturbance and general malaise were frequently observed. Chemical cystitis (hematuria) could be prevented by adequate water intake.

UI MeSH Term Description Entries
D007069 Ifosfamide Positional isomer of CYCLOPHOSPHAMIDE which is active as an alkylating agent and an immunosuppressive agent. Isofosfamide,Isophosphamide,Asta Z 4942,Holoxan,Iphosphamide,Iso-Endoxan,NSC-109,724,NSC-109724,Iso Endoxan,NSC 109,724,NSC 109724,NSC109,724,NSC109724
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D002294 Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed) Carcinoma, Epidermoid,Carcinoma, Planocellular,Carcinoma, Squamous,Squamous Cell Carcinoma,Carcinomas, Epidermoid,Carcinomas, Planocellular,Carcinomas, Squamous,Carcinomas, Squamous Cell,Epidermoid Carcinoma,Epidermoid Carcinomas,Planocellular Carcinoma,Planocellular Carcinomas,Squamous Carcinoma,Squamous Carcinomas,Squamous Cell Carcinomas
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000230 Adenocarcinoma A malignant epithelial tumor with a glandular organization. Adenocarcinoma, Basal Cell,Adenocarcinoma, Granular Cell,Adenocarcinoma, Oxyphilic,Adenocarcinoma, Tubular,Adenoma, Malignant,Carcinoma, Cribriform,Carcinoma, Granular Cell,Carcinoma, Tubular,Adenocarcinomas,Adenocarcinomas, Basal Cell,Adenocarcinomas, Granular Cell,Adenocarcinomas, Oxyphilic,Adenocarcinomas, Tubular,Adenomas, Malignant,Basal Cell Adenocarcinoma,Basal Cell Adenocarcinomas,Carcinomas, Cribriform,Carcinomas, Granular Cell,Carcinomas, Tubular,Cribriform Carcinoma,Cribriform Carcinomas,Granular Cell Adenocarcinoma,Granular Cell Adenocarcinomas,Granular Cell Carcinoma,Granular Cell Carcinomas,Malignant Adenoma,Malignant Adenomas,Oxyphilic Adenocarcinoma,Oxyphilic Adenocarcinomas,Tubular Adenocarcinoma,Tubular Adenocarcinomas,Tubular Carcinoma,Tubular Carcinomas
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

I Kohno, and M Kazuta, and J Miyao, and N Kunimi, and M Kawamoto, and T Tanimura, and K Fujiwara, and K Sekiba
January 1990, Cancer chemotherapy and pharmacology,
I Kohno, and M Kazuta, and J Miyao, and N Kunimi, and M Kawamoto, and T Tanimura, and K Fujiwara, and K Sekiba
January 2007, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,
I Kohno, and M Kazuta, and J Miyao, and N Kunimi, and M Kawamoto, and T Tanimura, and K Fujiwara, and K Sekiba
September 2007, Proteomics. Clinical applications,
I Kohno, and M Kazuta, and J Miyao, and N Kunimi, and M Kawamoto, and T Tanimura, and K Fujiwara, and K Sekiba
January 1990, Cancer chemotherapy and biological response modifiers,
I Kohno, and M Kazuta, and J Miyao, and N Kunimi, and M Kawamoto, and T Tanimura, and K Fujiwara, and K Sekiba
January 1996, Cancer chemotherapy and biological response modifiers,
I Kohno, and M Kazuta, and J Miyao, and N Kunimi, and M Kawamoto, and T Tanimura, and K Fujiwara, and K Sekiba
January 1992, Cancer chemotherapy and biological response modifiers,
I Kohno, and M Kazuta, and J Miyao, and N Kunimi, and M Kawamoto, and T Tanimura, and K Fujiwara, and K Sekiba
February 1989, Seminars in oncology,
I Kohno, and M Kazuta, and J Miyao, and N Kunimi, and M Kawamoto, and T Tanimura, and K Fujiwara, and K Sekiba
October 1982, American journal of reproductive immunology : AJRI : official journal of the American Society for the Immunology of Reproduction and the International Coordination Committee for Immunology of Reproduction,
I Kohno, and M Kazuta, and J Miyao, and N Kunimi, and M Kawamoto, and T Tanimura, and K Fujiwara, and K Sekiba
July 2000, Zhonghua zhong liu za zhi [Chinese journal of oncology],
I Kohno, and M Kazuta, and J Miyao, and N Kunimi, and M Kawamoto, and T Tanimura, and K Fujiwara, and K Sekiba
April 2014, Zhonghua fu chan ke za zhi,
Copied contents to your clipboard!